Skip to main content
SpringerLink
Log in

Bevacizumab

  • Chapter
  • First Online:
Adverse Events with Biomedicines

  • 1225 Accesses

Abstract

Bevacizumab (Avastin®, Genentec) is a recombinant humanized monoclonal IgG1k antibody specifically binding to soluble vascular endothelial growth factor (VEGF-A), and thus inhibiting its interaction with the respective receptors Flt-1 (VEGFR-1), KDR (VEGFR-2), and Ftl-4 (VEGF-3) located at the surface of endothelial cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Avastin® (bevacizumab). Prescribing Information. Genentec May 2012

    Google Scholar 

  2. FDA Memorandum to the file BLA 125085 Avastin (bevacizumab) Dec 2010

    Google Scholar 

  3. Avastin® (Bevacizumab) Medicines Product Information. Genentech. (www.gen.com)

  4. Avastin® (Bevacizumab) BL 125085/169 Briefing Book Feb 2009

    Google Scholar 

  5. Avastin® (Bevacizumab) EPAR Product Information WC50002927 EMA Sept 2012

    Google Scholar 

  6. Avastin® (Bevacizumab) EMA Assessment Report WC 500029270 March 2008

    Google Scholar 

  7. Avastin® (Bevacizumab) EMA Refusal Assessment Report WC500075000 Jan 2010

    Google Scholar 

  8. Avastin® (Bevacizumab) BL 125085/191-192 Briefing Book July 2010

    Google Scholar 

  9. Avastin® (Bevacizumab) EMA WC500029271 Annex I Sept 2012

    Google Scholar 

  10. Ferrara N, Davys-Smith T (1997) The biology of vascular endothelial growth factor. Endocrine Rev 18:14–25

    Google Scholar 

  11. Konno H, Yamamoto M, Ohta M (2010) Recent concepts of angiogenic therapy. Surg Today 40:494–500

    Article  PubMed  Google Scholar 

  12. Carmelier P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307 doi: 10.1038/nature10144

    Google Scholar 

  13. Gressett SM, Shah SR (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43:490–501

    Article  PubMed  CAS  Google Scholar 

  14. Avastin® (Bevacizumab) FDA Primary Clinical Review STN 125085/0 Part 1, Feb 2004

    Google Scholar 

  15. Kabbinavar FF, Flynn PJ, Kozloff M et al (2012) Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer 48:1126–1132

    Article  PubMed  CAS  Google Scholar 

  16. Abu-Hejleh T, Mezhir JJ, Goodheart MJ et al (2012) Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 14:277–284

    Article  PubMed  CAS  Google Scholar 

  17. Hayman SR, Leung N, Grande JP et al (2012) VEGF inhibition, hypertension and renal toxicity. Curr Oncol Rep 14:285–294

    Article  PubMed  CAS  Google Scholar 

  18. Avastin® (Bevacizumab) BL 125085/191-Briefing Book June 2010

    Google Scholar 

  19. Troeltsch M, Woodlock T, Kriegelstein S et al (2012) Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc 78(c85):1–7

    Google Scholar 

  20. Ang CS-P, Kemeny NE (2011) Bevacizumab in the management of colon cancer: a review. J Solid Tumors 1:120–131

    Google Scholar 

  21. van Cutsem E, Vervenne WL, Bennouna Y et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231–2237

    Article  PubMed  Google Scholar 

  22. Stopeck AT, Unger JM, Rimsza LM et al (2012) A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non Hodgkin’s lymphoma: SWOG 0515. Blood doi:10.1182/blood-2012-04-423079 (online pre-publication)

  23. Sfakianos GP, Numnum TM, Halverson CB et al (2009) The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective study. Gynecol Oncol 114:424–426

    Article  PubMed  CAS  Google Scholar 

  24. Randall LM, Monk BJ (2010) Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117:497–504

    Article  PubMed  CAS  Google Scholar 

  25. Tanyi JL, McCann G, Hagemann AR et al (2011) Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 120:464–469

    Article  PubMed  CAS  Google Scholar 

  26. Schumcker C, Elken C, Agostini HT et al (2012) A safety meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS ONE 7(8):e42701. doi:10.1371/journal.pone.0042701

    Article  Google Scholar 

  27. Campbell RJ, Gill SS, Bronskill SE et al (2012) Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ. doi:10.1136/bmj.e4203

    Google Scholar 

  28. Ebos JML, Kerbel RS (2011) Angiogenic therapy: impact on invasion, disease progression and metastasis. Nat Rev Clin Oncol 8:210–221

    Article  PubMed  CAS  Google Scholar 

  29. Jutley G, Shona OA, Cheong Leen R et al (2012) Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma. Arch Ophthalmol 130:1466–1470

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 57 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Bevacizumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_10

Download citation

Publish with us

Policies and ethics

Search

Navigation